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OVERVIEW
Sporadic Alzheimer’s disease (AD; idio-
pathic, of unknown origin) is associ-
ated with dysfunctional gene expression in
the limbic system and entorhinal cortex
of the brain that drives amyloidogenesis,
pro-inflammatory signaling, alterations
in innate-immunity and related AD-
type neuropathology (Colangelo et al.,
2002; Lukiw, 2004; Ginsberg et al., 2012;
Kikuchi et al., 2013). While the pri-
mary visual cortex (Brodmann Area 17)
and the retina appear to be initially
spared of AD-type changes that devas-
tate the hippocampal CA1 and tempo-
ral lobe neocortex (Brodmann Area 22),
these primary sensory and signal process-
ing elements of the visual system become
more involved as AD progresses. Recent
data indicate that in moderate to late-stage
AD, pro-inflammatory and amyloidogenic
pathology spreads along the entorhinal-
primary visual sensory cortex-thalamic-
retinal axis, and this may be responsible in
part for the complex visual disturbances,
such as spatial and visual agnosia, facial
identification problems, perceptual distur-
bances, and visual hallucinations, associ-
ated with end-stages of the AD process
(Cui et al., 2007; Dehabadi et al., 2014;
Tzekov and Mullan, 2014; Zhao et al.,
2014). This “Opinion paper” will com-
ment on current trends in our under-
standing of specific amyloidogenic and
pro-inflammatory changes in the human
primary visual cortex and retina as AD
advances with particular reference to: (i)
the expression of the pro-inflammatory
marker cyclooxygenase-2 (COX-2); (ii) the
appearance and aggregation of Aβ42 pep-
tides; (iii) epigenetic mechanisms involv-
ing microRNA (miRNA) signaling that
appear to be associated with disease prop-
agation; and (iv) how direct and non-
invasive analysis of the retina may help to
detect and diagnose AD.
COX-2 AND BRAIN AND RETINAL
DEGENERATION
A family of cyclooxygenase (COX)
enzymes in the brain and retina constitutes
a group of prostaglandin-endoperoxide
synthases (PTGSs) responsible for the
formation of several prostanoid-types of
pro-inflammatory mediators including
prostaglandins, prostacyclins, throm-
boxanes, and leukotrienes (Yang and
Chen, 2008; Cudaback et al., 2014).
Cycooxygenase-2 (COX-2; EC 1.14.99.1;
72 kDa) is the inducible, NF-kB-regulated
isotype of the PTGSs, and as the rate-
limiting enzyme of the arachidonic acid
cycle is up-regulated in anatomical regions
of AD brain where it potentiates inflam-
matory neuropathology (Lukiw and
Bazan, 1998; Bazan and Lukiw, 2002;
Hoozemans et al., 2008; Lukiw et al.,
2012a,b; Cudaback et al., 2014). COX-2
expression, mean abundance, activity, and
signaling is significantly up-regulated in
both AD and age-related macular degener-
ation (AMD), a progressive degeneration
of the human retina pathologically sim-
ilar in many ways to the neocortical
degeneration observed in AD neocortex
(Hoozemans et al., 2008; Dinet et al., 2013;
Rodríguez Diez et al., 2013). Notably, sub-
retinal injection of Aβ42 peptides using
C57BL/6J mouse models was found to sig-
nificantly induce COX-2 expression up to
6-fold while compromising the integrity
of the blood-brain barrier and inducing
retinal inflammation, photoreceptor cell
death and driving a progressive retinal
degeneration (Dinet et al., 2013). While
COX-2 remains a major player in the
generation of oxygen radicals and lipid
mediators in propagating inflammation in
degenerating neocortex and retina, a third
COX enzyme cyclooxygenase-3 (COX-3)
may play ancillary roles in membrane-
based COX signaling, however the role of
COX-3 in AD and progressive neocortical
and retinal disease is understudied and
not well-understood (Cui et al., 2004; Wu
and Wan, 2010). Importantly, pathogenic
factors associated with aging or the later
stages of both brain and retinal degen-
erative disease may be important in the
course, development and progression of
each disease and what cell types, tissues,
or pathways may be preferentially affected
(Cui et al., 2007; Cao et al., 2013; Dehabadi
et al., 2014). It is interesting that as AD
advances there is a progressive and sequen-
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tial elevation in the pro-inflammatory
gene expression marker COX-2 from the
limbic system (where AD originates) into
the primary visual cortex and retina,
and this is accompanied by parallel ele-
vations in Aβ42 peptide abundance and
inflammation across the entire entorhinal-
primary visual cortex-thalamic-retinal
axis (Cui et al., 2007; Kruck et al., 2008;
Fang et al., 2009; Alexandrov et al., 2011;
Cao et al., 2013; Cudaback et al., 2014).
This is highly suggestive that soluble,
pathogenic signaling factors such as COX-
2, Aβ42 peptides or other relatively small
and mobile molecules such as miRNA
(see below) may be important intercellular
carriers of disease signals that eventually
connect the brain and retina (Zhao et al.,
2006; Tzekov and Mullan, 2014; Zhao
et al., 2014).
AD AND Aβ42 PEPTIDES
All forms of AD are characterized
neuropathologically by the progressive
appearance of intracellular neurofibrillary
tangles and dense, mostly extracellular,
insoluble Aβ42 peptide-enriched lesions
known as senile plaques (Alexandrov
et al., 2011; Sivak, 2013; Hardy et al.,
2014). Aβ42 peptides which form
the central core of the senile plaque
are generated by a complex series of
secretase-mediated cleavage events from
the neuronal-enriched, polytopic beta-
amyloid precursor protein (βAPP; Hardy
et al., 2014). The very presence of Aβ42
peptides in any tissue or physiologi-
cal circuit also implicates the existence
of sufficient βAPP precursor and sev-
eral functional membrane-associated
accessory proteins—beta and gamma
secretases, presenilin, and nicastrin for
example—which are required for effi-
cient Aβ42 peptide generation (Hardy
et al., 2014; Zhao et al., 2014). βAPP, the
enzymatic machinery required to generate
Aβ42 peptides, the Aβ42 peptides them-
selves, and their fibrillar and/or oligomeric
aggregates are considerably enriched in
both the hippocampal CA1/association
neocortex and sensory retina as AD
progresses (Alexandrov et al., 2011; Ohno-
Matsui, 2011; Lukiw et al., 2012a,b; Cao
et al., 2013; Sivak, 2013; Zhao et al., 2014).
Indeed both the progressively deposited
senile plaques of AD and the drusen
of AMD contain high concentrations of
Aβ42 monomers, dimers, and oligomers
aggregated at their cores (Alexandrov
et al., 2011; Ohno-Matsui, 2011; Lukiw
et al., 2012a,b; Sivak, 2013; Zhao et al.,
2014). One recent study reported Aβ42
peptides accumulating up to 9-fold and
greater over controls in the retina of
advanced AD patients, and Aβ42 pep-
tides were found to be increased ∼19-fold
or greater over controls in the retinas of
aging Tg2576 mice (a transgenic amy-
loid over-expressing murine model of
AD; TgAD), and a remarkable 53-fold
or more over controls in the retina of the
advanced 5xFAD murine TgAD model
(Lukiw et al., 2012b; Zhao et al., 2014).
From these and other data it is clear that as
AD or AMD initiates and progresses, Aβ42
peptides and pro-inflammatory markers
(such as COX-2) sequentially populate
the hippocampus and neocortex, the pri-
mary visual cortex and then the retina.
This is further supported by the temporal
pattern of progressive Aβ42 peptide depo-
sition in TgAD models as their phenotype
develops (Lukiw et al., 2012b; Tzekov and
Mullan, 2014). Interestingly, the degree of
visual problems reported by AD patients
has a strong correlation with the degree
of Aβ42 and related amyloidogenic and
pro-inflammatory markers in the primary
visual cortex when short post-mortem
interval brains are examined for the
expression of genes involved in inflamma-
tory neurodegeneration. Themagnitude of
these defects appear to mirror the tempo-
ral sequence of declining cognitive status
in the AD patients, especially in late-onset
AD cases with more rapid progression
and in aged AD patients (Jellinger and
Bancher, 1998; Thompson et al., 2003;
Wilson et al., 2006; Cui et al., 2007; Tzekov
and Mullan, 2014; unpublished obser-
vations). Again, these findings suggest a
progressive and propagating component
of AD neuropathology that extends well
beyond the anatomical centers of the brain
where AD originates.
microRNA AND AD PROPAGATION
One hundred and eight years of AD
research has revealed that despite an
entorhinal/neocortical origin for AD in
the hippocampal CA1 and/or the supe-
rior temporal lobe (Brodmann area A22),
AD neuropathology eventually spreads
insidiously into the frontal, parietal and
occipital lobes including the primary
visual cortex, and then to other suscepti-
ble, anatomically-connected regions of the
CNS including the retina (Alzheimer et al.,
1995; Zhao et al., 2006; Cui et al., 2007;
Zhao et al., 2014). The mechanism for this
spreading is not well-understood, but the
translocation of soluble pathogenic fac-
tors including small nucleic acids between
human brain cells, and between neural
cells and the cerebrospinal fluid have been
reported (Zhao et al., 2006; Pogue et al.,
2014). The finding that the abundance
and complexity of intraneural miRNAs
are often contiguous with the extra-
cellular fluid (ECF), and that the ECF
and cerebrospinal fluid (CSF) contain
many of the same pathogenic miRNAs,
such as the inducible, NF-kB-regulated
pro-inflammatory microRNAs miRNA-9,
miRNA-34a, miRNA-125b, miRNA-146a,
and miRNA-155, suggests that these
soluble, degeneration-associated single
stranded RNAs are capable of translo-
cating throughout the circulating fluids
of the CNS and perhaps into the blood
serum. It is our opinion that besides their
obvious diagnostic value, pharmacologi-
cal approaches aimed at down-regulating
overly abundant, pathogenic miRNAs by
using anti-miRNA strategies may ulti-
mately have application in the clinical
management of AD and AMD, and per-
haps other diseases with an amyloidogenic
and pro-inflammatory component (Cui
et al., 2010; Alexandrov et al., 2011; Zhao
et al., 2014).
CONCLUDING REMARKS
In summary, a picture is emerging of the
evolution of the AD phenotype as an
advancing, spreading or “propagating”
amyloidogenic and pro-inflammatory,
ultimately fatal, CNS dysfunction even-
tually manifesting as a more globalized
disorder than previously appreciated,
involving the brain’s limbic system, pri-
mary visual cortex and eventually the
sensory retinal systems, especially in the
later stages of AD. It still remains unclear
whether AD neuropathology evolves inde-
pendently in the limbic system, primary
visual cortex and retina, but current find-
ings suggest that there is a “continuity”
or “spreading” of the pathology from the
limbic system to the entorhinal-cortex-
visual cortex-retinal circuit. The cellular
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linkage of the hippocampal CA1 to the
primary visual cortex, from the primary
visual cortex to the thalamus, and from
the thalamus to the retinal ganglion can
involve as few as three neurons and their
processes, although many more different
types of neurons and complex circuitries
in the retinal-primary visual cortex con-
nectome have recently become apparent
that are required for homeostatic visual
processing (Cui et al., 2007; Masland,
2013; Dehabadi et al., 2014). The common
neuroectodermal origins of the neocortex
and retina may predispose these highly
integrated, multi-neuronal layered struc-
tures to AD-type dysfunction, including
the involvement of shared pathogenic
pathways that drive amyloidogenesis and
pro-inflammatory neurodegeneration.
Importantly, the retina is the only com-
ponent of the CNS that can be visualized
directly and non-invasively. We propose
that rigorous retinal examination includ-
ing electrooculography, high resolution
retinal imaging, ophthalmoscopy, optical
coherence tomography (OCT) analyzing
retinal nerve fiber layer (RNFL) thin-
ning and other parameters, visual evoked
potential (VEP) analysis, or combinations
of these and other advanced techniques
may have considerable value in the esti-
mation and diagnosis of early AD-type
change. It is our opinion that the inte-
gration of the data obtained from these
multiple non-invasive techniques of the
retina at various stages of AD may be
of useful diagnostic value as they should
be reflective of the structural and func-
tional pathologies originating in deeper
structures of the AD brain (Koch et al.,
2006; Kesler et al., 2011; Vaney et al., 2012;
Moreno-Ramos et al., 2013; Chang et al.,
2014; Dehabadi et al., 2014; Tzekov and
Mullan, 2014).
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